Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver diseases

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 554-561

  Hardwick, Rhiannon N ^a   Ferreira, Daniel W ^b   More, Vijay R ^c   Lake, April D ^a   Lu, Zhenqiang ^a   Manautou, Jose E ^b   Slitt, Angela L ^c   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' PHOSPHOADENOSINE 5' PHOSPHOSULFATE SYNTHASE 1; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2A3; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B28; GLUCURONOSYLTRANSFERASE 3A1; MESSENGER RNA; PARACETAMOL; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1C4; SULFOTRANSFERASE 2B1; SULFOTRANSFERASE 4A1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; GLUCURONIDATION; HUMAN; HUMAN TISSUE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN FUNCTION; SULFONATION;

ACETAMINOPHEN; BIOTRANSFORMATION; DISEASE PROGRESSION; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; LIVER; RNA, MESSENGER; SUBSTRATE SPECIFICITY; SULFONIC ACIDS; SULFOTRANSFERASES;

EID: 84874094715     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048439     Document Type: Article

References (38)

1. Adjei AA and Weinshilboum RM (2002) Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 292:402-408.
2. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
3. Ali R and Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41:265-278.
4. Bock KW (2010) Functions and transcriptional regulation of adult human hepatic UDPglucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem Pharmacol 80:771-777.
5. Brunt EM and Tiniakos DG (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16:5286-5296.
6. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
7. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
8. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
9. Debinski HS, Lee CS, Danks JA, Mackenzie PI, and Desmond PV (1995) Localization of uridine 59-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology 108:1464-1469.
10. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, and Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087-2094.
11. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22.
12. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ (2010) Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301.
13. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATPbinding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:2395-2402.
14. Hui Y, Yasuda S, Liu MY, Wu YY, and Liu MC (2008) On the sulfation and methylation of catecholestrogens in human mammary epithelial cells and breast cancer cells. Biol Pharm Bull 31:769-773.
15. Jancova P, Anzenbacher P, and Anzenbacherova E (2010) Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103-116.
16. Kiba T, Kintaka Y, Suzuki Y, Nakata E, Ishigaki Y, and Inoue S (2009) Ventromedial hypothalamic lesions change the expression of neuron-related genes and immune-related genes in rat liver. Neurosci Lett 455:14-16.
17. King BM (2006) The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 87:221-244.
18. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, and Unalp-Arida A, et al.; Nonalcoholic Steatohepatitis Clinical Research Network (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
20. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos 35:1970-1978.
21. Lindsay J, Wang LL, Li Y, and Zhou SF (2008) Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 9:99-105.
22. MacKenzie PI, Rogers A, Elliot DJ, Chau N, Hulin JA, Miners JO, and Meech R (2011) The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Mol Pharmacol 79:472-478.
23. Manautou JE, Tveit A, Hoivik DJ, Khairallah EA, and Cohen SD (1996) Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts. Toxicol Appl Pharmacol 140: 30-38.
24. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, and Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81.
25. McCullough AJ (2011) Epidemiology of the metabolic syndrome in the USA. J Dig Dis 12: 333-340.
26. Meech R and Mackenzie PI (2010) UGT3A: novel UDP-glycosyltransferases of the UGT superfamily. Drug Metab Rev 42:45-54.
27. Merrell MD and Cherrington NJ (2011) Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43:317-334.
28. Minchin RF, Lewis A, Mitchell D, Kadlubar FF, and McManus ME (2008) Sulfotransferase 4A1. Int J Biochem Cell Biol 40:2686-2691.
29. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drugdrug interaction potential. Drug Metab Rev 42:196-208.
30. Reisman SA, Csanaky IL, Aleksunes LM, and Klaassen CD (2009) Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. Toxicol Sci 109:31-40.
31. Riches Z, Stanley EL, Bloomer JC, and Coughtrie MW (2009) Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab Dispos 37:2255-2261.
32. Ritter JK (2000) Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171-193.
33. Rubinstein E, Lavine JE, and Schwimmer JB (2008) Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis 28:380-385.
34. Sanyal AJ (2011) NASH: A global health problem. Hepatol Res 41:670-674.
35. Wang XR, Qu ZQ, Li XD, Liu HL, He P, Fang BX, Xiao J, Huang W, and Wu MC (2010) Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection. Cancer Sci 101:412-415.
36. Yasuda S, Suiko M, and Liu MC (2005) Oral contraceptives as substrates and inhibitors for human cytosolic SULTs. J Biochem 137:401-406.
37. Yeo M, Na YM, Kim DK, Kim YB, Wang HJ, Lee JA, Cheong JY, Lee KJ, Paik YK, and Cho SW (2010) The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. Proteomics 10:266-276.
38. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KL (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27: 447-486.